Neil Castle

Summary

Affiliation: Icagen Inc
Country: USA

Publications

  1. ncbi Aquaporins as targets for drug discovery
    Neil A Castle
    Icagen, 4222 Emperor Boulevard, Suite 350, Durham, NC 27703, USA
    Drug Discov Today 10:485-93. 2005
  2. ncbi Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy
    Neil A Castle
    Icagen, Inc, Durham, NC 27703, USA
    Expert Opin Ther Pat 20:1471-503. 2010
  3. ncbi Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels
    N A Castle
    Icagen Inc, Durham, North Carolina 27703, USA
    Mol Pharmacol 63:409-18. 2003
  4. ncbi Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms
    Neil Castle
    Icagen Inc, Durham, North Carolina 27703, USA
    Comb Chem High Throughput Screen 12:107-22. 2009
  5. ncbi Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574)
    Aaron C Gerlach
    Icagen, Inc, Durham, NC 27703, USA
    Mol Pharmacol 77:58-68. 2010
  6. ncbi The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons
    Xin Su
    Icagen, Inc, Durham, North Carolina, USA
    Anesth Analg 109:632-40. 2009
  7. ncbi Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel
    Michael F Gross
    Icagen Inc, PO Box 14487, Research Triangle Park, NC 27709, USA
    Bioorg Med Chem Lett 17:2849-53. 2007
  8. ncbi Structure-activity relationship of a novel class of naphthyl amide KATP channel openers
    Sean C Turner
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, IL 60064, USA
    Bioorg Med Chem Lett 13:1741-4. 2003
  9. ncbi In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892
    Murali Gopalakrishnan
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Br J Pharmacol 143:81-90. 2004

Collaborators

Detail Information

Publications9

  1. ncbi Aquaporins as targets for drug discovery
    Neil A Castle
    Icagen, 4222 Emperor Boulevard, Suite 350, Durham, NC 27703, USA
    Drug Discov Today 10:485-93. 2005
    ..Consequently, aquaporins are attractive targets for the development of novel drug therapies for disorders that involve aberrant water movement, such as edema and kidney disease...
  2. ncbi Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy
    Neil A Castle
    Icagen, Inc, Durham, NC 27703, USA
    Expert Opin Ther Pat 20:1471-503. 2010
    ..Voltage-dependent potassium (Kv) channels help orchestrate many of the physiological and pathophysiological processes that promote and sometimes hinder the healthy functioning of our bodies...
  3. ncbi Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels
    N A Castle
    Icagen Inc, Durham, North Carolina 27703, USA
    Mol Pharmacol 63:409-18. 2003
    ..2. The results from this study show that maurotoxin is a potent inhibitor of the IK1 subclass of K(Ca) potassium channels and may serve as a useful tool for further defining the physiological role of this channel subtype...
  4. ncbi Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms
    Neil Castle
    Icagen Inc, Durham, North Carolina 27703, USA
    Comb Chem High Throughput Screen 12:107-22. 2009
    ....
  5. ncbi Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574)
    Aaron C Gerlach
    Icagen, Inc, Durham, NC 27703, USA
    Mol Pharmacol 77:58-68. 2010
    ..This compound may provide a useful tool to further understand the mechanism by which hERG channels inactivate and affect cardiac function in addition to the role of hERG channels in other cell systems...
  6. ncbi The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons
    Xin Su
    Icagen, Inc, Durham, North Carolina, USA
    Anesth Analg 109:632-40. 2009
    ..In this study, we examined structurally diverse kappa-ORAs for their abilities to inhibit tetrodotoxin-resistant (TTX-r) sodium channels in adult rat DRGs...
  7. ncbi Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel
    Michael F Gross
    Icagen Inc, PO Box 14487, Research Triangle Park, NC 27709, USA
    Bioorg Med Chem Lett 17:2849-53. 2007
    ..Kv1.5 inhibitors have the potential to be atrium-selective agents for treatment of atrial fibrillation. (1R,2R)-1 has an IC(50) of 0.033microM against Kv1.5 and is selective against other cardiac ion channels, including hERG...
  8. ncbi Structure-activity relationship of a novel class of naphthyl amide KATP channel openers
    Sean C Turner
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, IL 60064, USA
    Bioorg Med Chem Lett 13:1741-4. 2003
    ..2/SUR2B cells and pig bladder strips. Additionally, A-151892 was found to selectively inhibit unstable bladder contractions in vivo in an obstructed rat model of myogenic bladder function..
  9. ncbi In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892
    Murali Gopalakrishnan
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Br J Pharmacol 143:81-90. 2004
    ....